We tested the antiproliferative activities of fluphenazine and sertraline in 5 representative NSCLC cell lines harboring mutations in EGFR or not: H522 (EGFR WT), A549 (EGFR WT; KRAS mutation), H1975 (EGFR T790M mutation), PC9 (EGFR 19-bp deletion in exon 19), and PC9/R (Figure 1D). Here, KRAS is linked to non-small cell lung carcinoma.